Medeon Biodesign Statistics
Total Valuation
Medeon Biodesign has a market cap or net worth of TWD 3.99 billion. The enterprise value is 2.82 billion.
Market Cap | 3.99B |
Enterprise Value | 2.82B |
Important Dates
The last earnings date was Friday, November 1, 2024.
Earnings Date | Nov 1, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Medeon Biodesign has 92.14 million shares outstanding. The number of shares has increased by 0.06% in one year.
Current Share Class | n/a |
Shares Outstanding | 92.14M |
Shares Change (YoY) | +0.06% |
Shares Change (QoQ) | +0.03% |
Owned by Insiders (%) | 11.52% |
Owned by Institutions (%) | 3.49% |
Float | 47.20M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 14.72 |
PB Ratio | 2.32 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -3.52 |
EV / Sales | 10.40 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -3.03 |
Financial Position
The company has a current ratio of 7.87, with a Debt / Equity ratio of 0.10.
Current Ratio | 7.87 |
Quick Ratio | 7.56 |
Debt / Equity | 0.10 |
Debt / EBITDA | n/a |
Debt / FCF | -0.19 |
Interest Coverage | -148.37 |
Financial Efficiency
Return on equity (ROE) is -39.77% and return on invested capital (ROIC) is -22.93%.
Return on Equity (ROE) | -39.77% |
Return on Assets (ROA) | -21.46% |
Return on Capital (ROIC) | -22.93% |
Revenue Per Employee | 6.95M |
Profits Per Employee | -20.55M |
Employee Count | 39 |
Asset Turnover | 0.11 |
Inventory Turnover | 11.02 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.41% in the last 52 weeks. The beta is 0.71, so Medeon Biodesign's price volatility has been lower than the market average.
Beta (5Y) | 0.71 |
52-Week Price Change | -2.41% |
50-Day Moving Average | 45.49 |
200-Day Moving Average | 44.77 |
Relative Strength Index (RSI) | 36.67 |
Average Volume (20 Days) | 70,624 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medeon Biodesign had revenue of TWD 270.93 million and -801.29 million in losses. Loss per share was -8.70.
Revenue | 270.93M |
Gross Profit | 72.84M |
Operating Income | -869.86M |
Pretax Income | -857.42M |
Net Income | -801.29M |
EBITDA | -827.77M |
EBIT | -869.86M |
Loss Per Share | -8.70 |
Balance Sheet
The company has 1.38 billion in cash and 179.21 million in debt, giving a net cash position of 1.20 billion or 13.06 per share.
Cash & Cash Equivalents | 1.38B |
Total Debt | 179.21M |
Net Cash | 1.20B |
Net Cash Per Share | 13.06 |
Equity (Book Value) | 1.75B |
Book Value Per Share | 18.65 |
Working Capital | 1.33B |
Cash Flow
In the last 12 months, operating cash flow was -865.51 million and capital expenditures -65.62 million, giving a free cash flow of -931.13 million.
Operating Cash Flow | -865.51M |
Capital Expenditures | -65.62M |
Free Cash Flow | -931.13M |
FCF Per Share | -10.11 |
Margins
Gross margin is 26.88%, with operating and profit margins of -321.06% and -295.75%.
Gross Margin | 26.88% |
Operating Margin | -321.06% |
Pretax Margin | -316.47% |
Profit Margin | -295.75% |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -343.67% |
Dividends & Yields
Medeon Biodesign does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.06% |
Shareholder Yield | -0.06% |
Earnings Yield | -20.10% |
FCF Yield | -23.34% |
Stock Splits
The last stock split was on August 23, 2023. It was a forward split with a ratio of 1.049992864.
Last Split Date | Aug 23, 2023 |
Split Type | Forward |
Split Ratio | 1.049992864 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |